Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A study uses '-omics' and artificial intelligence to derive a metric that distinguishes normal immunity from its perturbation — and reveals that healthy immune systems are less alike than anticipated.
Data collected from 138,015 hospital-based singleton births in four sub-Saharan African countries revealed an association between heat exposure in the week leading up to the birth and perinatal mortality.
A secure framework that harmonizes storage and querying of clinical and genetic data using blockchain technology was developed to support combined genotype–phenotype queries, improving transparency into how and when health information is used.
Tackling antimicrobial resistance will require a sustainable research and development ecosystem for antibiotic development, alongside strategies for responsible use and global access.
This Perspective calls for inclusion of patients with MASLD and measurement of liver outcomes in cardio–kidney–metabolic trials, when data suggest mechanistically plausible benefits and clinical safety—and outlines considerations for trial design and regulatory approval.
In this case series of patients with T cell acute lymphoblastic leukemia (T-ALL), therapy with CD7-directed CAR T cells that express an anti-CD7 protein expression blocker to prevent CAR T-induced fratricide showed encouraging rates of clinical response and persistence of circulating CAR T cells.
In this pragmatic, randomized clinical trial involving 1,196 pregnant and postpartum women from 6 hospitals in Nigeria, AI-based electrocardiogram screening proved accurate in detecting cardiomyopathies and suggests that it could improve detection of these conditions.
This participant-level pooled analysis of the three phase III trials that have tested the non-steroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and chronic kidney disease with type 2 diabetes provides an integrated view of the mortality, cardiovascular and renal effects of this treatment. Editor recognition statement: Primary Handling editor: Michael Basson, in collaboration with the Nature Medicine team.
In a multicenter, open-label, randomized controlled trial, digital consults including digital data sharing, patient e-learning and guideline recommendations to clinicians improved guideline-directed medical therapy over the course of 12 weeks.
Infections account for the highest number of non-relapse-related deaths after CAR T cell therapy, underscoring the necessity for clinical risk-mitigating strategies and a deeper understanding of CAR T cell-related cytopenia.
